Journal article

Soluble Receptor for Advanced Glycation End-products (sRAGE) and Colorectal Cancer Risk: A Case-Control Study Nested within a European Prospective Cohort

Elom K Aglago, Sabina Rinaldi, Heinz Freisling, Li Jiao, David J Hughes, Veronika Fedirko, Casper G Schalkwijk, Elisabete Weiderpass, Christina C Dahm, Kim Overvad, Anne Kirstine Eriksen, Cecilie Kyro, Marie-Christine Boutron-Ruault, Joseph A Rothwell, Gianluca Severi, Verena Katzke, Tilman Kuhn, Matthias B Schulze, Krasimira Aleksandrova, Giovanna Masala Show all

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | AMER ASSOC CANCER RESEARCH | Published : 2021

Abstract

BACKGROUND: Overexpression of the receptor for advanced glycation end-product (RAGE) has been associated with chronic inflammation, which in turn has been associated with increased colorectal cancer risk. Soluble RAGE (sRAGE) competes with RAGE to bind its ligands, thus potentially preventing RAGE-induced inflammation. METHODS: To investigate whether sRAGE and related genetic variants are associated with colorectal cancer risk, we conducted a nested case-control study in the European Prospective Investigation into Cancer and Nutrition (EPIC). Plasma sRAGE concentrations were measured by ELISA in 1,361 colorectal cancer matched case-control sets. Twenty-four SNPs encoded in the genes associat..

View full abstract

Grants

Awarded by Wereld Kanker Onderzoek Fonds, as part of the World Cancer Research Fund International grant program


Awarded by Regional Government of Murcia


Awarded by Instituto de Salud Carlos II (ISCIII RETIC, Spain)


Awarded by Cancer Research UK


Awarded by Medical Research Council


Awarded by Fondation de France (FDF)


Funding Acknowledgements

F The funding for this work (WCRF 2015/1391, to principal investigator, M. Jenab) was obtained from Wereld Kanker Onderzoek Fonds, as part of the World Cancer Research Fund International grant program. The authors thank the EPIC study participants and staff for their valuable contribution to this research. The authors especially thank Mr. Bertrand Hemon and Dr. Aurelie Moskal for their support in preparing the databases and providing technical support pertaining to the data analysis, along with Ms. Audrey Brunat-Manquat for her assistance with the laboratory analyses for sRAGE. The coordination of the EPIC study was financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts were supported by Danish Cancer Society (Denmark); Ligue Contre le Cancer, Institut Gustave Roussy, Mutuelle Generale de l'Education Nationale, and Institut National de la Sante et de la Recherche Medicale (INSERM, France); German Cancer Aid, German Cancer Research Center (DKFZ), and Federal Ministry of Education and Research (BMBF, Germany); Italian Association for Research on Cancer (AIRC), National Research Council, Associazione Iblea per la Ricerca Epidemiologica (AIRE-ONLUS) Ragusa, Associazione Volontari Italiani Sangu (AVIS) Ragusa, and the Sicilian Government (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), and Statistics Netherlands (the Netherlands); Health Research Fund (FIS); Regional Governments of Andalucia, Asturias, Basque Country, Murcia (No. 6236) and Navarra; the Centro de Investigacion Biomedica en Red en Epidemiologia y Salud Publica and Instituto de Salud Carlos II (ISCIII RETIC, RD06/0020, Spain); Health Research Fund (FIS) Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology -ICO (Spain); Swedish Cancer Society, Swedish Scientific Council, and Regional Government of Skane and Vasterbotten (Sweden); Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and the Wellcome Trust (United Kingdom). This work was also supported by grants from Cancer Research UK (14136 to EPIC-Norfolk; and C570/A16491, C8221/A19170, and C8221/A29017 to EPIC-Oxford) and Medical Research Council (1000143 to EPIC-Norfolk and MR/M012190/1 to EPIC-Oxford, United Kingdom). The EPIC-Norfolk study (DOI 10.22025/2019.10.105.00004) has received funding from the Medical Research Council (MR/N003284/1 and MC-UU_12015/1) and Cancer Research UK (C864/A14136). The authors are grateful to all the participants who have been part of the project and to the many members of the study teams at the University of Cambridge (Cambridge, England) who helped enable this research. This work was partially financially supported by the Fondation de France (FDF, grant no. 00081166 to H. Freisling and R. Cordova and FDF grant no. 00089811 to A.-L. May~en).